Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.


23 rd January 2021 marks the second annual BPDCN Awareness Day (#BPDCNday) since it received its own classification as a distinct hematologic malignancy by the World Health Organization (WHO).
ELZONRIS is the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, in Europe.
SEL24/MEN1703 is being Evaluated for the Treatment of Acute Myeloid Leukemia (AML) Poster Accepted for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting
Menarini Ricerche today announced the results of the dose escalation part of its B-PRECISE-01 clinical trial (NCT03767335) which is evaluating MEN1611,
Menarini Ricerche, the R&D division of the Menarini Group, announced today that it has treated the first patient in Europe for the cohort expansion part of DIAMOND-01 clinical trial
Page 1 of 5First   Previous   [1]  2  3  4  5  Next   Last   


Concession granted by Italian Ministry for Cultural Heritage and Activities Read more